Trial · NCT03178201
TGR1202 in Relapsed and Refractory Follicular Lymphoma
NCT03178201, Phase 2, Terminated, Columbia University; results first posted 2021-07-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TGR1202 in Relapsed and Refractory Follicular Lymphoma. Trials, record NCT03178201. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03178201
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TGR1202 in Relapsed and Refractory Follicular Lymphoma
- NCT number
- NCT03178201
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Follicular Lymphoma
- Interventions
- TGR-1202
- First posted
- 2017-06-06
- Last updated
- 2021-07-16
- Results first posted
- 2021-07-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | Up to 3 years | The sum of patients with partial responses and complete responses. |
| Secondary | Progression Free Survival (PFS) After Treatment With TGR-1202 | Up to 3 years | The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. |
| Secondary | Duration of Response (DoR) After Treatment With TGR-1202 | Up to 3 years | The time of initial response until documented tumor progression. |
| Secondary | Number of Dose Delays | Up to 3 years | The number of instances of patients having a dose of study drug delayed 1 or more days. |
| Secondary | Number of Dose Reductions | Up to 3 years | The number of instances of patients having to reduce the dosage of study drug based on specified toxicities. |
| Secondary | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Up to 3 years | Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\] broken down by adverse event and CTCAE v4.0 grade of each event. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. | ||
| SECONDARY | Progression Free Survival (PFS) After Treatment With TGR-1202 | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. | ||
| SECONDARY | Duration of Response (DoR) After Treatment With TGR-1202 | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. | ||
| SECONDARY | Number of Dose Delays | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. | ||
| SECONDARY | Number of Dose Reductions | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. | ||
| SECONDARY | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Up to 3 years | The data was not collected or analyzed due to the study was terminated prematurely due to slow to accrual and PI left the institution. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | TGR-1202 | 5 | |
| Overall Study | COMPLETED | TGR-1202 | 0 | |
| Overall Study | NOT COMPLETED | TGR-1202 | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | TGR-1202 | 0 | 5 |
| Total, other adverse events | TGR-1202 | 0 | 5 |
| Total, serious adverse events | TGR-1202 | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03178201
GET https://conductscience.org/api/trials/v1/NCT03178201/registered